General Atlantic, WuXi AppTec lead $98m Series D in CANbridge Pharma

CANbridge Pharmaceutical Inc that is focused on rare disease therapies has raised $98 million in its Series D round led by global private equity firm General Atlantic and existing investor WuXi AppTec, a Hong Kong and Shanghai dual-listed innovative drug maker, according to a company statement.